Thank you. For Rigaku, my name is Kawakami. Thank you very much for being here despite your busy schedules. This is the first earnings meeting after the IPO, so we would like to do our best. Now, without further ado, as was just introduced, I'd like to take you through what we have announced today: the midterm business plan of the company. That's what I'd like to start with for the midterm plan. In September 2023, this was formulated, and after that, in October last year, we had an IPO, and we had an investment story we communicated to the investors at the time of the IPO. The story is the same, but we have made some updates. However, there is a consistency between the investment story at the time of IPO and the midterm business plan we are announcing today.
This should give you clear ideas about our growth going forward. Please also access the full document. The entire document is available on the company website. I would like to give you a highlight here. Rigaku is a globally operating, highly profitable, and high-growth specialized manufacturer of analytical and measurement solutions centered on X-rays. We have sales of JPY 90.6 billion, Adjusted EBITDA margin of nearly 26%, a CAGR of more than 20% for the last several years, and an overseas sales ratio of 73%. We have a high global share, which is equivalent to the global leader in X-ray metrology. There are three segments. One is multipurpose analytical instruments, analysis, and handling of X-rays. Mainly, this is used for the R&D purposes at companies and academia.
And using the same principle of X-ray technology, not only in R&D but also in process control of semiconductors, our technology is used. Our instrument is used. This is 26%. And there are services we are providing based on those instruments. We are also selling instruments outside. This is about 29%. And the use markets include electronic parts and semiconductors. We also cover other industry sectors: metals, batteries, petrochemicals, ceramics, and security. In the material science area, our X-ray equipment is indispensable. Rigaku's unique strength is, as you can see here, X-ray-related core technologies and instruments: optical equipment, analyzers, and analysis software. All of these are produced in-house, and we have a vertical integration model. Therefore, to the needs of customers, one by one, we are applying each one of these basic technologies to provide the best solution to the customers. This is the strength of the company.
And also, this is Rigaku's growth strategy. There are three pillars. The first pillar is the basic strategy. Our origin is the multipurpose analytical instruments. And the material science is very advanced today, and very precise analysis is required in today's society. So using our basic technology in the applied areas with the X-ray basic technologies, we have an overwhelming market share here in Japan. We still have a lot of room to grow in overseas markets. So we are focused on the growth in overseas. That is the focus today of the company. So in this first pillar, multipurpose analytical instruments, we would like to grow our share. The second pillar is the so-called Lab to Fab strategy. Using the same X-ray technology, we are applying our technology to the production facilities, not only the laboratories. The first successful case was semiconductor.
We would like to move forward with other sectors as well. In the area of semiconductor, the materialization and stacking technology is advancing. X-ray technology is becoming more and more important, becoming a share number one. Or we're already number one, but we'd like to solidify our position here in the semiconductor industry. And also, in new areas like optical and CD instrumentation, we would like to combine these with X-ray so that we can provide the hybrid technologies in new areas. Further, advanced packaging testing markets, we are planning to enter into those new markets beyond semiconductors. In the semiconductor process control market, we'd like to achieve a high market share. And the pillar three is the application of this Lab to Fab strategy to areas other than semiconductor. Using the same X-ray principle, we will start with R&D and then move on to the production sites.
In the power semiconductor, this is already happening. Furthermore, in the future, for battery, battery materials, and life science areas, we would like to emulate the same success that we have had in the semiconductor. This is how we would like to accelerate our growth. So these are the three pillars of strategy. So by promoting these three pillars, what are our midterm targets? First of all, in the top line, continuously, we would like to achieve 10% or double-digit growth from 2023 to 2027. By doing so, sales should reach JPY 115 billion-JPY 120 billion. This is the target. And the breakdown of this is multipurpose analytical instruments. The market is growing at 5%, but in that market, we are increasing our share. Therefore, 7% growth is our target.
In the semiconductor process control equipment, using the X-ray metrology, well, the market is 9%, but we'd like to double the growth, 18% CAGR. This is our target. Furthermore, in components and service, especially in the service business, we are growing this service business. In total, we would like to achieve 8% CAGR. That's the target. By blending those three areas, 10% growth for the total company is. This is the target for the entire company. In terms of the margin, as of 2027, 27% EBITDA margin is what we want to achieve. This translates into the following. As we grow, continue to grow, well, the R&D and the global infrastructure are the areas where we are investing. Therefore, the margin improvement itself may not be so great.
However, originally, we already had a very high margin, and this margin percentage, even after the investment into R&D and the structure of the organization, we would like to achieve the increase in the margin percentage as well. Therefore, R&D would increase from 5% or 6% to 9% of the sales going forward. That's the R&D investment. So that's the target for the midterm. By implementing this midterm target and the strategies, now, please take a look at our target for FY 2025.
Okay. So, I mean, taking into consideration the midterm plan, now I'd like to talk about the consolidated earnings for the full year FY 2024. First, take you through some of the highlights. So, overall highlights. So, last year, in October, we have released the outlook for the full year. We have significantly overachieved to that outlook. So, both on top line and bottom line, we were able to achieve double-digit growth. Like we have mentioned, so we had improvement in product mix. So we have invested into R&D and foundation, building foundation of business. But at the same time, we were able to enhance our margin. So that's a very big highlight for our overall achievement. Now, if you look at the performance by product category, multipurpose analytical instrument, we are able to enhance our global market share. So we are achieving midterm plan.
Especially, we are growing in the Asian market. So, due to that, we are able to achieve 15% growth, which is significantly above market average. Semiconductor process control instrumentation. In this business, many things happen. But the biggest factor is the AI semiconductor, GAA generation chip. Our X-ray metrology is being applied to GAA. It's growing there. And that's the overall driver of 25% high rate growth. So that's the highlight for the performance in FY 2024. Next phase is the quantification of what I've just mentioned. So we show year-on-year growth through these graphs. So our sales grow 13.5% to JPY 19.6 billion. Our adjusted EBITDA grew by 16% to JPY 23.4 billion. So our margin has rose to 25.9%, and our margin improved by 0.6%. Adjusted profit grew from JPY 12.9 billion to JPY 15.3 billion. So that's + JPY 1.4 billion above outlook.
The margin has rose from 16.3%-17.0%. The absolute value of profit grew by 18.4%. Profit margin grew by 0.7%. So, as you can see, we have solidly grown both our top line and bottom line. So that's to summarize the FY 2024 earnings. Overall, I'm going to take you through the performance by different product categories. Multipurpose analytical instruments, like we have mentioned, 15% growth. In a global market outside Japan, we have achieved 19% growth. So we are able to enhance our market share in global market, which is our strategy. And in each respective global market, we have increased application staff, sales, service staff. So we have built and invested into commercial infrastructure to support this level of growth. Furthermore, we have increased the number of labs globally. So we have invested successfully to achieve 19% top line growth outside Japan.
Now, if you look at this by region, last year, China and Asia grew quite substantially. In China, so I mean, this was achieved for our competitors as well. As an analytical, I mean, they had a very significant supplemental budget for analytical devices. So that has led to significant growth in academia, field of academia, especially university. In Asia, India, Korea, we saw growth in these markets. So Asia overall grew almost 30%. So other factors drove the growth of this product category, but global growth has really driven the growth of this product category. So the significant supplementary budget has contributed to about an additional JPY 3 billion of revenue for us. If you look at this by different market, academia, government has grown quite significantly because of this factor.
Another point about this product category, multipurpose analytical instruments: the highlight for last year in the first half of 2024. So the pillar three strategy, the third pillar, was very successful. So Lab to Fab in the field of SiC for the power semiconductors, very big instruments, equipment. This has grown quite significantly in the first half of 2024. The success changed rather in the second half, but in the first half, we had a pillar three strategy which progressed quite successfully, Lab to Fab. So that has driven growth. So these large-scale equipment, higher value-added equipment, has grown. So that has improved our product mix. And we had a down-to-earth pricing strategy implementation in the region. So we were able to grow our operating profit by 15%-17%. So that was the summary of multipurpose analytical instruments business. Next, semiconductor process control instruments business.
2024, like I have mentioned, we had 25% very substantial growth. Now, if you look at the big picture, if you look at the memory market, the recovery is slower than we had expected. So in the memory market, we are not able to grow. But we were able to make up for that downside by three drivers of growth last year. One is the GAA, including GAA AI chips. I mean, our technology was adopted in both North America and Asia, both for development and mass production. In these two regions, we captured the application for GAA chips. We are able to go there. Advanced logic, foundry, are the applications which we have acquired to achieve significant increase in the top line. So it was an unprecedented growth of our top line in that sense. The second factor is our growth towards SPE, semiconductor production equipment manufacturer group.
We have been intentional in approaching the overall semiconductor production ecosystem. Not only foundry or chip manufacturers, we have been selling to SPEs. Last year, we saw the fruit of this effort. SPEs, I mean, so because of so they want to adopt technology used by foundries or IDMs. They want to measure the precision of their equipment by the same device that their customers are using. That's why they are using micrometric instrumentation. They are using that for their R&D and inspection before shipment. Our effort has really paid off in the last year. We were able to achieve JPY 5.4 billion sales to SPE manufacturers. On top of that, if you look at China, we are not too dependent on China. 17% on consolidated basis, 17% in the semiconductors business. That's the dependency on China.
The leading-edge investment was restricted in many ways in China. They focused on legacy and power semiconductors when it comes to investment, and we were able to capture such demand quite well. These three factors, I mean, have led to significant growth, 25% growth of the business. Our margin has declined moderately. Our gross margin has actually went up. But because of the investment for, I mean, enhancing our sales and services for a new round of growth has caused a slight decline in our operating margin. Still, our operating margin is still very high, 31.7%. The remaining component service product capacity, so 2% growth year-on-year, moderate growth. Service continued to grow with the growth of install base and strengthening of global organization, 12%, a very solid growth. Especially if you look at Americas, maintenance contract value grew substantially.
Multiple-year subscription-type maintenance contract, full-fledged maintenance contract is becoming very, very popular. We want to take all these and expand that to outside Europe and the United States, into Asia and Japan. Parts. So cybersecurity, but if you look at parts, so EUV, multi-layer mirror, which makes a significant portion of this business. Because of elongated inventory adjustment on the customer's end, the sales didn't grow. And together with the sales of other components and non-X-ray analytical devices, we have a number of different categories of product in this segment. Overall, the category was not able to grow last year.
So on top of the top line growth, we had margin growth, as I said, 25.3%-25.9%. There was an accretion growth. It's not a big accretion, but there was a positive accretion. And the GP is increasing because of the mix and the pricing. And the improvement in GP gross margin for the R&D and SG&A expenses, there was an offsetting by this. So as a result, we were able to achieve 0.6 percentage point accretion. So that was my brief explanation about FY 2024 top line as well as margin. In general, as I mentioned earlier, the mid-term business plan, the overall direction is to grow top line by double-digit. And while doing the growth investment, we were going to achieve accretive improvement. And that was something we have achieved actually in FY 2024.
And for next, I'd like to talk about the FY 2025 business strategy and earnings forecast. The first page is about the highlight. In total, we were able to maintain, we will maintain the growth trajectory based on the midterm plan, and 7.8% is the growth target, top line. And in terms of the FX, our assumption is JPY 145 to the dollar. And compared with JPY 152.2 this year's average, the new assumption is a very conservative assumption. If the FX rate is the same, and then top line growth would be 10% or 10.2% without the impact of FX. So that's the projection or plan for FY 2025. Having said that, we have to carefully watch the interest rate and FX trends going forward. We wanted to be a little bit conservative in the assumption. And based on that, we have formulated the cost planning that would be more prudent.
That's why we used the assumption rate of JPY 145 to the dollar. In that sense, on this assumption, EBITDA of JPY 25 billion, adjusted OP of, and net income are as shown here on the chart. But without the FX, EBITDA margin is 26.1%. There will be an accretion like we did. Adjusted OP margin would be 23%. It will be almost flat. And adjusted net income is 16%. There is a positive increase. The growth trajectory will be maintained in line with the midterm plan. That's the projection for 2025. Another highlight for 2025 is the production capacity expansion and the shortening of lead time. That would allow us to go into the next stage in the development of supply chain. If you look at the future, in order for Rigaku to achieve a higher expectation and higher sales, this is very important.
So that is something we like to do in 2025. That's for the overall company, and later on, we will talk about each segment one by one. In the multipurpose analytical instrumentation, we are thinking about 4% growth without FX, because in the past two years, there was a rapid growth, so it's a slower growth, and also because of the lack of Chinese budgetary benefit we had last year, this is a slower growth, and the Chinese economic growth is, this is supposed to be the sales growth is negative, but in other areas, we will cover up for that, so let me talk about more details later in my presentation. As for semiconductor process control instruments, we would like to continue a strong growth of 20%.
Because the whole picture is changing for the semiconductor this year, rather than logic and foundry, we would like to focus on leading-edge memories because the investment will be recovering, so we like to capture the demand and attain growth. Continuously, we will focus on GAA advanced package demand and further growth should be attained from GAA advanced package. We would like to also enhance the adoption by SPE manufacturers. That way, we would like to continue with a growth of 20%, so let me go back to multipurpose analytical instruments. The actual is 4% growth. That's the target. This is lower growth compared with this year or FY 2024, but this is inclusive of China, excluding China, we will have a 12% revenue growth, so 4% growth is lower than in the previous year, but for the CAGR from 2023 to 2025, it will be 8%.
So this is still based on the midterm trajectory. In terms of the demand for X-ray analytical instruments, there will be more advancement in the material analysis for the next generation power device materials like gallium nitride and gallium oxide. The R&D will proceed further. Therefore, we like to respond to these demands. And furthermore, in the battery area, the all-solid-state battery is the area where we are seeing the start of mass production. So there will be a shift from Lab to Fab. So this is a great driver for the growth for our instruments. And also, global infrastructure upgrade will be continued. And Shanghai, Silicon Valley, Taiwan, Boston, Frankfurt application labs and technology centers will be expanded in these areas. And also, our sales offices and channels will be expanded in India and Taiwan, China. And we will expand and open new channels.
And the overseas headcount for sales organization, application scientists will be also increased. And by doing so, we would like to continue to expand the global market share. And enhancement of core technologies and components will be proceeded. For next generation materials evaluation, high energy resolution detectors, namely XTRAIA series, has been launched last year. We are further developing this product so that we can increase our performance. And this new version will be launched into the market. As for the evaluation of microscope and trace materials, we have powerful X-ray sources and optical elements called MicroMax series. We are expanding this as well. Furthermore, for the material informatics, automation of analytical instruments with a focus on this will be promoted. And we are commercializing MiniFlex XpC. So the pillar three strategy will be promoted further.
In this area, in March, at the beginning of the month, we are planning to hold an IR day where we will share with you a more in-depth discussion. But let me give you some highlights. For the pillar three semiconductor electronic components, the SiC market, well, production is shifting quickly to China. Therefore, from Japan or Europe, it seems that the market is shrinking, but the demand for SiC itself is still very strong. The production will be in China, however, and crystal defect analysis market, there is a lot of room for development, so we will have an upside here, and in Japan, gallium nitride and next-gen materials investment will be very active. So we would like to approach customers' R&D units. So that's the pillar three strategy for battery and battery materials. As I said, the all-solid material development is proceeding.
The pilot line or assembly cell is where we are getting the adoption. Eventually, we want to get the adoption in the mass production lines. Our strength is material development, especially crystal analysis in mass production. We can do this. Therefore, using this advantage, assembly cell and assembly line business is what we are seeking using X-ray transfer and X-ray analysis. This is where we want to differentiate ourselves. In the all-solid-state battery production line, the Pillar Three strategy is to open up the application there. Life science is a midterm challenge. We developed moleculize for protein analysis and recently opened a laboratory in Boston where we are testing samples and getting good reactions from customers. This is featured even in the Nature magazine. We would like to even pursue higher technology and development in these areas.
And semiconductor process control, I mentioned it a little bit, but in FY 2025, advanced logic and foundry expansion is what we want to do. There will be some slowdown, but the sales level will continue to be high because the GAA generation logic, there will be more demand for our products and the mass production is starting. So we think we can expand. For the next generation package, adoption is starting in the latter half of this fiscal year. That's what we are expecting. Therefore, for advanced logic and foundry market, there may be some slowdown, but still the demand level is continuing to be high. And this year's growth is in the memory market because in that market, it's not the PC or smartphones, but the driver will be the data centers and the AI chips. So HBM and 3D NAND. These will be used by data centers.
So in these areas, we like to achieve growth for the leading-edge memories. And there will be recovery in this market. So we are expecting some growth here. And HBM will be more sophisticated, high-performance chip manufacturers, memory manufacturers. Yield improvement is critical for them. Therefore, our X-ray instruments, there is a very high, strong inquiries from them. So in the HBM market, we are expecting high growth. At the same time, so memory is another area where we are expecting growth. And SPE manufacturer business, it was strong in 2024, but we believe that there will be a strong demand in 2025. And collaboration with some other players is something we are seeking as well in this area. Furthermore, for the further growth in the future, we are making some preparations rather than just focusing on the short term.
Three areas. One is the further expansion of advanced measurement solutions and advanced logic. Here, we want to focus on high-k with higher dielectric constant as a metal gate which uses these materials. There are increased demand for needs of such materials. So we want to develop products and capability which allows us to do that. And GAA, a CFET process eventually would require silicon germanium, silicon. So we need technology to measure and assess these materials. So this would be our future growth driver. In the field of advanced packaging, so this is about AI chip evolution. It's a very hot topic. So because there's hundreds of thousands of microbumps and TSVs per package. And those microbumps and TSVs have to be tested from outside, but we don't have effective technology for doing that. So that's why we are working with our customer to develop this technology.
We have progressed to the piloting using beta machine, so we are using machine learning for imaging, and that's how we are conducting these testing. It's an innovative technology which we should be able to release in the near future. The third factor, hybrid metrology, so this is a hybrid between optical and our technology, so we're going to work with the optical players, focus on high throughput of optical technology, combine that with a very precise 3D analytical capability of X-ray. We combine them to offer optimized solution to our customers. We believe we can do that, and we will leverage on AI software platform to optimize the solution, so again, speed with the optical, and where required, we use X-ray for increased precision, so that's the hybrid metrology technology that we are developing as we speak right now.
We are going to talk about these three technologies in a bit more detail in our IR day in March. Manufacturing capacity expansion. We have our capacity in Yamanashi, Osaka, and our external partner. Altogether, we are going to increase our capacity by 50% and shorten our lead time. We have planned production for components. We are going to base our production on forecast and the modularization. We will have a scheduled production, not make to order. We will leverage on pipeline information, customer information to speed up the start of production. By doing so, we are going to compress on the lead time from orders to delivery. We are eyeing on shortening the lead time by 30% in three years. This year, for some product, we should be able to shorten the lead time by 50%.
So overall, by 2027, we want to double the production capacity, both through the expansion of production space and shortening of lead time. That should be complete by 2025. And the outlook for FY 2025, putting everything together. So we are expecting targeting 10% growth. Now, but the balance, our sales is skewed towards the second half. A number of different reasons. Because a memory market will start recovering from the second half of next year, or this year, excuse me. And production capacity would be fully capitalized from the second half. So our top line would be skewed towards second half. And if you look at the first half, it may look like a negative growth. But in the first half of 2024, grew by 29%. So we are maintaining that level of sales in the first half of this year.
We are not being too conservative in that account. We are going to, we'll be positioning ourselves for even more significant growth in the second half. If you look at the CapEx, this year is going to be the peak of CapEx expansion of Yamanashi and investment into clean room is going to bring up CapEx to 9%. A consolidated payout ratio is going to be 30%. This would be identical to last year. Full year outlook for dividend payout is 18.8% per share. Adjusted ROE will continue to stay at very high level, 17.6%, almost 18%. That's the overall picture for 2025 for shareholder return. We will continue to grow in line with midterm plan, substantially double-digit growth and margin accretion. We will continue the path.
We are going to bring innovation to supply chain, which is going to bring our production to a new stage. The market will continue to evolve and change. The application will continue to change. The regions will change. Given that, we want to be flexible in adapting to change to achieve short-term objectives and purpose. At the same time, I mean, a continuous technology and product development to grow over midterm and longer term. Hybrid metrology or advanced packaging, we will continue our R&D initiatives in this area. Rigaku will achieve both short-term growth and mid-long-term growth. That we will continue to do in FY 2025. We will be going into the new stage of growth in the near future. I would like to ask for your continued support of all the stakeholders.
Like I mentioned, early March, we are scheduling IR day to talk about our, especially our technology, in a bit more detail. So with those additional information, we would like to communicate meticulously to the investor community about our strategy and our technology. I'm looking forward for further communication. Thank you very much for your kind attention. Thank you.